← All trials
NCT05679024
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 17, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2028
- First posted
- Jan 10, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 1400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- County of StockholmLead sponsor
- Uppsala UniversityCollaborator
- Uppsala UniversityStudy chair
- Karolinska InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.